This inventor holds 2 USPTO granted patents. Top assignee: Santaris Pharma A/s. Active years: 2013.
Location History:
- Karlslunde, DK (2013)
- Karlslunde, DE (2013)
Company Filing History:
Years Active: 2013
Title: Martin Munk: Innovator in Pharmaceutical Compositions
Introduction
Martin Munk is a notable inventor based in Karlslunde, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of microRNA related diseases. With a total of 2 patents, Munk's work is paving the way for innovative therapeutic approaches.
Latest Patents
Munk's latest patents focus on pharmaceutical compositions designed for the treatment of diseases sensitive to drugs that downregulate the function of microRNAs, mRNA, non-coding RNA, or viral genomes. His research has revealed that a long-term effect of an anti-microRNA oligonucleotide can be achieved when administered to primates. This discovery is crucial as it relates to the development of pharmaceutical compositions and methods for treating primates, including humans, with a long time interval between administrations.
Career Highlights
Martin Munk is currently associated with Santaris Pharma A/S, where he continues to advance his research in pharmaceutical innovations. His work is characterized by a commitment to improving treatment options for diseases that are challenging to manage with existing therapies.
Collaborations
Munk collaborates with esteemed colleagues such as Niels Abrahamsen and Elisabeth S Hildebrandt-Eriksen. Their combined expertise enhances the research and development efforts at Santaris Pharma A/S.
Conclusion
Martin Munk's contributions to pharmaceutical compositions represent a significant advancement in the treatment of microRNA related diseases. His innovative approach and collaborative efforts are likely to lead to impactful developments in the field.